SCHEDULE: RA Capital Maintains 9.9% Stake in Adicet Bio

RA Capital Management and its affiliates report maintaining a 9.9% beneficial ownership in Adicet Bio, Inc. as of June 30, 2026, primarily through RA Capital Healthcare Fund, L.P.

Summary

• RA Capital Management, L.P., along with its affiliates Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., have filed an amended Schedule 13G.
• As of June 30, 2026, the reporting persons collectively beneficially own 935,486 shares of Adicet Bio, Inc. common stock, representing 9.9% of the class.
• This ownership level is maintained despite the presence of a 'Beneficial Ownership Blocker' in pre-funded warrants held by RA Capital Healthcare Fund, L.P., which limits exercise to maintain ownership below 9.99%.
• The filing confirms that RA Capital serves as the investment adviser for the Fund and has been delegated sole voting and dispositive power over the securities held by the Fund.
• The reporting persons certify that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant but stable ownership stake by a major institutional investor, with no immediate red flags but also no strong buy signals.

Positives

• Significant institutional ownership maintained by a known investment firm (RA Capital Management).
• The ownership stake remains at a substantial 9.9%, indicating continued confidence or strategic interest.
• The filing clarifies the reporting structure and delegation of voting/dispositive power, providing transparency.

Negatives

• The 'Beneficial Ownership Blocker' in the pre-funded warrants limits the Fund's ability to exercise them fully, capping potential upside from warrant exercise.
• The filing is an amendment to a previous filing, indicating a status update rather than a new strategic development.

Risks

• The 'Beneficial Ownership Blocker' restricts the Fund from increasing its stake beyond 9.99% through warrant exercise, potentially limiting future participation in company growth.
• The filing does not provide specific details on the rationale behind maintaining this stake, leaving investor motivations open to interpretation.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Adicet Bio. It is a disclosure of beneficial ownership by RA Capital Management.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G/A.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that RA Capital Management is a prominent healthcare-focused investment firm known for taking significant stakes in biotechnology and pharmaceutical companies. Their continued 9.9% ownership in Adicet Bio, a company in the cell therapy space, suggests ongoing strategic interest, though the capped ownership due to warrant blockers indicates a specific investment strategy rather than an intent for outright control or a significant increase in stake.

Stakeholder Impact

• Shareholders: The continued significant ownership by RA Capital may provide a degree of stability and signal institutional confidence, but the capped ownership limits potential for aggressive stake-building.
• Management: The filing confirms RA Capital's non-control-oriented investment purpose, aligning with typical institutional investor disclosures.
• Creditors/Suppliers: No direct impact is indicated by this ownership filing.

Next Steps

• The filing does not outline specific next steps for RA Capital Management beyond maintaining their current ownership position.
• Adicet Bio, Inc. will continue its operations, and future disclosures will indicate any changes in ownership or corporate actions.

Key Dates

Keywords

Adicet Bio, RA Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Healthcare Fund, Common Stock, Warrants